The faculty open the episode by discussing how most patients with hormone receptor-positive, HER2-negative metastatic breast cancer begin treatment with a CDK4/6 inhibitor plus an aromatase inhibitor and many respond well, sometimes for years.
ESR1 Mutation Emergence and the SERENA-6 Treatment Strategy in First-Line Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma
2
CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications
3
How KRAS-Targeted Therapy May Advance Toward Cancer Prevention
4
Subcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC
5